Wound Care Biologics Market, By Product Type (Biologic Skin Substitutes, Enzyme Based Formulations, and Growth factors), By Application (Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers) and Acute Wounds ( Surgical Wounds and Burns)), By End User (Hospital, Clinics, Ambulatory Surgical Centers, and Home Care Settings), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Wound care biologics are bioengineered products used for non-healing wounds of lower extremity. Wound care biologics involves use of active biological agents such as plant and animal-derived biomolecules which exhibits antioxidant and antimicrobial properties. They used in the post surgeries and trauma cases as they provide moist healing environment aiding heat loss, protein, and prevent bacterial contamination. Biologics used for treatment of wound has grown exponentially in the recent years. Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity. Many different products are also been manufactured to replace or augment various substrates in the wound healing cascade. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Wound care biologics market accounted for US$ 1.66 billion in 2020 and is estimated to be US$ 3.88 billion by 2030 and is anticipated to register a CAGR of 9.8%.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Increasing incidence of traumatic and other patients

Increasing incidences of traumatic, surgical, ulcers and burn wounds are the major driver factor of wound care biologics. In 2017, according to global diabetes community it was estimated that 422 million adults are living with diabetes globally, and this is expected to increase to 642 million by 2040.

Further, rising medical tourism in Asia Pacific also drives the wound care biologics market. In 2016, according to the survey by Brink Global Risk Center, 2017, around 4 million medical tourists traveled to India for health care services, 3.5 million foreign patients travelled to Thailand and 900,000 patients to Singapore, with the number expected to grow by 10%–14% by 2020.

Moreover, the higher cost of the biologics and stringent regulatory approvals for launch of innovative tissue engineered products are hindering growth of the wound care biologics market.

Wound care biologics market is segmented on the basis of product type, application, end-user, and region.

On the basis of product type, the wound care biologics market is categorized into biologic skin substitutes, enzyme based formulations, and growth factors. On the basis of applications, the target market is classified into chronic wounds and acute wounds. Further, chronic wounds sub-segment is classified into diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Acute wounds sub-segment is segmented into surgical wounds and burns. On the basis of end-user, the wound care biologics market is bifurcated into hospital, clinics, ambulatory surgical centers, and home care settings.

Regional Insights:

On the basis of region, the wound care biologics market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.  The market in North America is expected to account for major revenue share as compared to that of other regions. This can be attributed to high prevalence of diabetic foot ulcers, high presence of key players, and availability of a variety of wound biologics products in the countries of the region. Also, the market in Europe is expected to account for second-highest revenue share in the global market, followed by the market in Asia Pacific.

Segments Covered in Report:

Wound Care Biologics Market, By Product Type:

• Biologic Skin Substitutes
• Enzyme Based Formulations
• Growth factors

Wound Care Biologics Market, By Application:

• Chronic Wounds
• Diabetic Foot Ulcers
• Venous Leg Ulcers
• Pressure Ulcers
• Acute Wounds
• Surgical Wounds
• Burns

Wound Care Biologics Market, By End User:

• Hospital
• Clinics
• Ambulatory Surgical Centers
• Home Care Settings

Wound Care Biologics Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Key players operating in the wound care biologics market includes Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, Skye Biologics, Inc., Alphatec Holdings, Inc., Solsys Medical, LLC, Amino Technology LLC, and Osiris Therapeutics, Inc.

• Smith & Nephew Plc.
  •   Osiris Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  •   Amino Technology LLC
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  •  Solsys Medical LLC
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Alphatec Holdings, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  •  Skye Biologics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  •  Integra Lifesciences Holdings Corporation
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  •   Organogenesis, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance